# Discovery of Two Structurally Distinct Classes of Inhibitors Targeting the Nuclease MUS81 and Enhancing Efficacy of Chemotherapy in Cancer Cells

## TL;DR

Researchers discovered two new types of inhibitors that target the MUS81 nuclease, potentially improving cancer chemotherapy by disrupting DNA repair.

## Contribution

The discovery of two structurally distinct small-molecule inhibitors of MUS81 with potential therapeutic and research applications.

## Key findings

- MU262 and MU876 inhibit MUS81 activity in vitro and in cells.
- The inhibitors sensitize cancer cells to DNA-damaging agents by impairing DNA repair.

## Abstract

Nucleases are promising pharmacological targets due to
their essential
role in maintaining genomic stability. They are crucial for regulation
of cell viability, and their modulation is exploitable in disease
prevention and treatment, including cancer. The conserved structure-specific
endonuclease MUS81 resolves branched DNA intermediates during replication,
repair, and recombination. Aberrant MUS81 activity causes DNA damage,
chromosomal abnormalities, and genome instability, contributing to
oncogenesis. Thus, pharmacological targeting of MUS81 is an attractive
yet underexplored therapeutic strategy. We describe the discovery
of two chemically distinct small-molecule classes of MUS81 inhibitors,
exemplified by compounds MU262 and MU876. Both compounds effectively
inhibit MUS81 in vitro and in cells, sensitizing cancer cells to DNA-damaging
agents by impairing DNA repair. These inhibitors can also serve as
chemical biology tools for a deeper study of MUS81 function and as
leads for drug discovery aimed at therapies exploiting DNA repair
vulnerabilities in cancer treatment.